MWNA
FPRX

Marshall Wace North America’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Marshall Wace North America’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-67,575
Closed -$2.77M – 1708
2017
Q3 		$2.77M Sell
67,575
-273,812
-80% -$8.6M 0.02% 709
2017
Q2 		$10.2M Buy
341,387
+56,058
+20% +$1.75M 0.07% 311
2017
Q1 		$10.3M Buy
+285,329
New +$12.6M 0.08% 260
2013
Q4 		$314K Buy
+18,700
New +$232K 0.01% 595

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Marshall Wace North America's FPRX Position: Q4 2017 in Review

Marshall Wace North America sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 67,575 shares — an estimated $2.77M sold.

Marshall Wace North America first reported a position in FPRX in Q4 2013 and held it in 4 quarters. The position peaked at $10.3M in Q1 2017. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

  • Marshall Wace North America reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Marshall Wace North America sold 67,575 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $2.77M.
  • Marshall Wace North America first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 4 quarters.
  • Marshall Wace North America's Five Prime Therapeutics, Inc. position peaked at $10.3M in Q1 2017.
  • 137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.